Clovis Oncology (CLVS) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Clovis Oncology Announces 2018 Operating Results
February 26, 2019 8:00 AM EST2018 Rubraca® (rucaparib) U.S. sales totaled $95.4M, including $30.4M for the fourth quarter of 2018 Rubraca EU approval granted January 2019 for ovarian cancer maintenance treatment indication; launch in Germany to initiate on this Friday, March 1 Robust Clovis-sponsored Rubraca development program in place; enrollment ongoing for clinical studies in ovarian, prostate and bladder cancers Targeting late 2019 for supplemental NDA filing for BRCA-mutant advanced prostate cancer, pending data maturity; interim data update expected at Fall 2019 medical meeting Initial... More
